Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C14H11Cl2NO2 |
| Molecular Weight | 296.149 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=CC=C(Cl)C(NC2=C(C=CC=C2)C(O)=O)=C1Cl
InChI
InChIKey=SBDNJUWAMKYJOX-UHFFFAOYSA-N
InChI=1S/C14H11Cl2NO2/c1-8-6-7-10(15)13(12(8)16)17-11-5-3-2-4-9(11)14(18)19/h2-7,17H,1H3,(H,18,19)
Meclofenamic acid, used as Meclofenamate sodium, is a non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. Meclofenamate sodium capsules are indicated for the relief of mild to moderate pain, for the treatment of primary dysmenorrhea and for the treatment of idiopathic heavy menstrual blood loss; for relief of signs and symptoms of juvenile arthritis; so as for relief of the signs and symptoms of rheumatoid arthritis; For relief of the signs and symptoms of osteoarthritis. The mode of action, like that of other nonsteroidal anti-inflammatory agents, is not known. Therapeutic action does not result from pituitary-adrenal stimulation. In animal studies, meclofenamate sodium was found to inhibit prostaglandin synthesis and to compete for binding at the prostaglandin receptor site. In vitro, meclofenamate sodium was found to be an inhibitor of human leukocyte 5-lipoxygenase activity. These properties may be responsible for the anti-inflammatory action of meclofenamate sodium. There is no evidence that meclofenamate sodium alters the course of the underlying disease.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2094253 |
|||
Target ID: CHEMBL215 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Palliative | MECLOFENAMATE SODIUM Approved UseMeclofenamate sodium capsules are indicated: For reduction of fever in adults; For relief of mild to moderate pain in adults; For relief of signs and symptoms of juvenile arthritis; For relief of the signs and symptoms of rheumatoid arthritis; For relief of the signs and symptoms of osteoarthritis; For treatment of primary dysmenorrhea; For acute or long-term use in the relief of signs and symptoms of the following: Ankylosing spondylitis; Acute painful shoulder (Acute subacromial bursitis/supraspinatus tendinitis); Acute gouty arthritis. Meclofenamate sodium capsules are also indicated for the treatment of idiopathic heavy menstrual blood loss. As with all nonsteroidal anti-inflammatory drugs, selection of meclofenamate sodium capsules require a careful assessment of the benefit/risk ratio. Veclofenamate sodium capsules are not recommended in children because adequate studies to demonstrate safety and efficacy have not been carried out. Launch Date5.26089585E11 |
|||
| Palliative | MECLOFENAMATE SODIUM Approved UseMeclofenamate sodium capsules are indicated: For reduction of fever in adults; For relief of mild to moderate pain in adults; For relief of signs and symptoms of juvenile arthritis; For relief of the signs and symptoms of rheumatoid arthritis; For relief of the signs and symptoms of osteoarthritis; For treatment of primary dysmenorrhea; For acute or long-term use in the relief of signs and symptoms of the following: Ankylosing spondylitis; Acute painful shoulder (Acute subacromial bursitis/supraspinatus tendinitis); Acute gouty arthritis. Meclofenamate sodium capsules are also indicated for the treatment of idiopathic heavy menstrual blood loss. As with all nonsteroidal anti-inflammatory drugs, selection of meclofenamate sodium capsules require a careful assessment of the benefit/risk ratio. Veclofenamate sodium capsules are not recommended in children because adequate studies to demonstrate safety and efficacy have not been carried out. Launch Date5.26089585E11 |
|||
| Palliative | MECLOFENAMATE SODIUM Approved UseMeclofenamate sodium capsules are indicated: For reduction of fever in adults; For relief of mild to moderate pain in adults; For relief of signs and symptoms of juvenile arthritis; For relief of the signs and symptoms of rheumatoid arthritis; For relief of the signs and symptoms of osteoarthritis; For treatment of primary dysmenorrhea; For acute or long-term use in the relief of signs and symptoms of the following: Ankylosing spondylitis; Acute painful shoulder (Acute subacromial bursitis/supraspinatus tendinitis); Acute gouty arthritis. Meclofenamate sodium capsules are also indicated for the treatment of idiopathic heavy menstrual blood loss. As with all nonsteroidal anti-inflammatory drugs, selection of meclofenamate sodium capsules require a careful assessment of the benefit/risk ratio. Veclofenamate sodium capsules are not recommended in children because adequate studies to demonstrate safety and efficacy have not been carried out. Launch Date5.26089585E11 |
|||
| Palliative | MECLOFENAMATE SODIUM Approved UseMeclofenamate sodium capsules are indicated: For reduction of fever in adults; For relief of mild to moderate pain in adults; For relief of signs and symptoms of juvenile arthritis; For relief of the signs and symptoms of rheumatoid arthritis; For relief of the signs and symptoms of osteoarthritis; For treatment of primary dysmenorrhea; For acute or long-term use in the relief of signs and symptoms of the following: Ankylosing spondylitis; Acute painful shoulder (Acute subacromial bursitis/supraspinatus tendinitis); Acute gouty arthritis. Meclofenamate sodium capsules are also indicated for the treatment of idiopathic heavy menstrual blood loss. As with all nonsteroidal anti-inflammatory drugs, selection of meclofenamate sodium capsules require a careful assessment of the benefit/risk ratio. Veclofenamate sodium capsules are not recommended in children because adequate studies to demonstrate safety and efficacy have not been carried out. Launch Date5.26089585E11 |
|||
| Palliative | MECLOFENAMATE SODIUM Approved UseMeclofenamate sodium capsules are indicated: For reduction of fever in adults; For relief of mild to moderate pain in adults; For relief of signs and symptoms of juvenile arthritis; For relief of the signs and symptoms of rheumatoid arthritis; For relief of the signs and symptoms of osteoarthritis; For treatment of primary dysmenorrhea; For acute or long-term use in the relief of signs and symptoms of the following: Ankylosing spondylitis; Acute painful shoulder (Acute subacromial bursitis/supraspinatus tendinitis); Acute gouty arthritis. Meclofenamate sodium capsules are also indicated for the treatment of idiopathic heavy menstrual blood loss. As with all nonsteroidal anti-inflammatory drugs, selection of meclofenamate sodium capsules require a careful assessment of the benefit/risk ratio. Veclofenamate sodium capsules are not recommended in children because adequate studies to demonstrate safety and efficacy have not been carried out. Launch Date5.26089585E11 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
15.1 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2322633/ |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
MECLOFENAMIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
30.2 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2322633/ |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
MECLOFENAMIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2322633/ |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
MECLOFENAMIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Doses
| Dose | Population | Adverse events |
|---|---|---|
400 mg 1 times / day multiple, oral Dose: 400 mg, 1 times / day Route: oral Route: multiple Dose: 400 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: rheumatoid arthritis Sources: |
Other AEs: Diarrhoea... |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Diarrhoea | 400 mg 1 times / day multiple, oral Dose: 400 mg, 1 times / day Route: oral Route: multiple Dose: 400 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: rheumatoid arthritis Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Meta-analysis of dyspepsia and nonsteroidal antiinflammatory drugs. | 2003 Aug 15 |
|
| Comparison of the in vivo coronary action of endothelin-1 and vasopressin role of nitric oxide and prostanoids. | 2003 Dec |
|
| Variable effects of nonsteroidal antiinflammatory agents on thyroid test results. | 2003 Dec |
|
| Interactions between vasoconstrictors and vasodilators in regulating hemodynamics of distinct vascular beds. | 2003 Oct |
|
| Analysis of responses to St. John's Wort in the feline pulmonary vascular bed. | 2004 |
|
| Effects of lornoxicam on the physiology of severe sepsis. | 2004 Dec |
|
| Responses to bradykinin are mediated by NO-independent mechanisms in the rat hindlimb vascular bed. | 2004 Dec |
|
| Myogenic reactivity is enhanced in rat radial uterine arteries in a model of maternal undernutrition. | 2004 Jul |
|
| Vasopressin effects on the coronary circulation after a short ischemia in anesthetized goats: role of nitric oxide and prostanoids. | 2004 Jul 14 |
|
| Roles for prostaglandins in the steroidogenic response of human granulosa cells to high-density lipoproteins. | 2004 Jul 30 |
|
| Determination of expression of cyclooxygenase-1 and -2 isozymes in canine tissues and their differential sensitivity to nonsteroidal anti-inflammatory drugs. | 2004 Jun |
|
| Race-specific differences in endothelial function: predisposition of African Americans to vascular diseases. | 2004 Jun 1 |
|
| Topical NSAIDs for acute pain: a meta-analysis. | 2004 May 17 |
|
| Coronary action of endothelin-1 and vasopressin during acute hypertension in anesthetized goats. Role of nitric oxide and prostanoids. | 2004 May-Jun |
|
| Compounds exhibiting selective efficacy for different beta subunits of human recombinant gamma-aminobutyric acid A receptors. | 2004 Nov |
|
| Analysis of gamma-aminobutyric acid-mediated responses in the pulmonary vascular bed of the cat. | 2004 Sep |
|
| Embryo transfer in the dromedary camel (Camelus dromedarius) using asynchronous, meclofenamic acid-treated recipients. | 2005 |
|
| Meclofenamic acid and diclofenac, novel templates of KCNQ2/Q3 potassium channel openers, depress cortical neuron activity and exhibit anticonvulsant properties. | 2005 Apr |
|
| Increased myogenic tone in 7-month-old adult male but not female offspring from rat dams exposed to hypoxia during pregnancy. | 2005 Aug |
|
| Tracking acidic pharmaceuticals, caffeine, and triclosan through the wastewater treatment process. | 2005 Jan |
|
| Mechanisms of the protective effects of urocortin on coronary endothelial function during ischemia-reperfusion in rat isolated hearts. | 2005 Jun |
|
| Coronary effects of endothelin-1 and vasopressin during acute hypotension in anesthetized goats. | 2005 Jun 10 |
|
| Biomarkers of oxidative stress study III. Effects of the nonsteroidal anti-inflammatory agents indomethacin and meclofenamic acid on measurements of oxidative products of lipids in CCl4 poisoning. | 2005 Mar 15 |
|
| Enhanced response of pig coronary arteries to endothelin-1 after ischemia-reperfusion. Role of endothelin receptors, nitric oxide and prostanoids. | 2005 Nov 7 |
|
| Nonsynaptic GABA signaling in postnatal subventricular zone controls proliferation of GFAP-expressing progenitors. | 2005 Sep |
|
| Determination of fourteen non-steroidal anti-inflammatory drugs in animal serum and plasma by liquid chromatography/mass spectrometry. | 2006 |
|
| Starch-based microspheres produced by emulsion crosslinking with a potential media dependent responsive behavior to be used as drug delivery carriers. | 2006 Apr |
|
| Early aging and anatomic heterogeneity determine cyclooxygenase-mediated vasoconstriction to angiotensin II in mice. | 2006 Aug |
|
| Role for prostaglandins in the regulation of type 1 11beta-hydroxysteroid dehydrogenase in human granulosa-lutein cells. | 2006 Dec |
|
| Allosteric modulation of [3H]EBOB binding to GABAA receptors by diflunisal analogues. | 2006 Dec |
|
| Partial renal ischemia elicits heterogeneous control of renal sympathetic nerve activity to ischemic and nonischemic regions of the kidney. | 2006 Feb |
|
| QSAR analysis of meclofenamic acid analogues as selective COX-2 inhibitors. | 2006 Jan 15 |
|
| Vasoconstrictor prostanoids may be involved in reduced coronary reactive hyperemia after ischemia-reperfusion in anesthetized goats. | 2006 Jan 20 |
|
| Antiepileptic effect of gap-junction blockers in a rat model of refractory focal cortical epilepsy. | 2006 Jul |
|
| Use of accelerating solvent extraction for detecting non-steroidal anti-inflammatory drugs in horse feces. | 2006 Jun |
|
| Intermedin/adrenomedullin-2 dilates the rat pulmonary vascular bed: dependence on CGRP receptors and nitric oxide release. | 2006 Jun |
|
| Second-order calibration of excitation-emission matrix fluorescence spectra for the determination of N-phenylanthranilic acid derivatives. | 2006 Mar |
|
| Angiotensin-(1-7) potentiates responses to bradykinin but does not change responses to angiotensin I. | 2006 Nov |
|
| Inhibition of human phenol and estrogen sulfotransferase by certain non-steroidal anti-inflammatory agents. | 2006 Oct |
|
| Meclofenamic acid extends donor-recipient asynchrony in equine embryo transfer. | 2006 Sep |
|
| Hemopressin, a hemoglobin fragment, dilates the rat systemic vascular bed through release of nitric oxide. | 2006 Sep |
|
| Cyclooxygenase-2 inhibition normalizes arterial blood pressure in CYP1A1-REN2 transgenic rats with inducible ANG II-dependent malignant hypertension. | 2006 Sep |
|
| Analysis of responses to kava kava in the feline pulmonary vascular bed. | 2006 Spring |
|
| Spurious urine excretion drug profile in the horse due to bedding contamination and drug recycling: the case of meclofenamic acid. | 2007 Apr |
|
| Alpha2-adrenoreceptor mediated sympathoinhibition of heart rate during acute hypoxia is diminished in conscious prostacyclin synthase deficient mice. | 2007 Apr |
|
| Molecular expression and pharmacological identification of a role for K(v)7 channels in murine vascular reactivity. | 2007 Jul |
|
| Non-steroidal anti-inflammatory drugs increase insulin release from beta cells by inhibiting ATP-sensitive potassium channels. | 2007 Jun |
|
| Simultaneous determination of various pharmaceutical compounds in water by solid-phase extraction-liquid chromatography-tandem mass spectrometry. | 2007 Jun 22 |
|
| Differential effects of losartan and candesartan on vasoconstrictor responses in the rat. | 2007 Mar-Apr |
|
| Endothelium-dependent relaxation of isolated splanchnic arteries from cirrhotic patients: Role of reactive oxygen species. | 2007 Oct |
Sample Use Guides
For Mild to Moderate Pain:
The recommended dose is 50 mg every 4 to 6 hours. Doses of 100 mg may be needed in some patients for optimal pain relief
For excessive menstrual blood loss and primary dysmenorrheal:
The recommended dose of meclofenamate sodium is 100 mg 3 times a day, for up to 6 days, starting at the onset of menstrual flow.
For rheumatoid arthritis and osteoarthritis (including acute exacerbations of chronic disease):
The dosage is 200 mg to 400 mg per day, administered in three or four equal doses.
Route of Administration:
Oral
The meclofenamic acid was tested in murine models immunodeficient and immunocompetent) of Uterine cervical cancer (UCC), which manifested a significant reduction in tumor growth and increased mouse survival. It was demonstrated that meclofenamic acid was the most cytotoxic, with a significant antitumor effect in murine models. Cytotoxicity assay performed with two repetitions. In a first selection assay meclofenamic acid was used in concentrations of 100 µM. In a subsequent assay, the mefenamic acid was used in concentrations of 0, 7.5, 15, 30, 60, 120 and 240 µM.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
LIVERTOX |
588
Created by
admin on Thu Jul 06 22:43:01 UTC 2023 , Edited by admin on Thu Jul 06 22:43:01 UTC 2023
|
||
|
WHO-ATC |
M01AG04
Created by
admin on Thu Jul 06 22:43:01 UTC 2023 , Edited by admin on Thu Jul 06 22:43:01 UTC 2023
|
||
|
WHO-VATC |
QM01AG04
Created by
admin on Thu Jul 06 22:43:02 UTC 2023 , Edited by admin on Thu Jul 06 22:43:02 UTC 2023
|
||
|
NCI_THESAURUS |
C1323
Created by
admin on Thu Jul 06 22:43:01 UTC 2023 , Edited by admin on Thu Jul 06 22:43:01 UTC 2023
|
||
|
CFR |
21 CFR 520.1330
Created by
admin on Thu Jul 06 22:43:01 UTC 2023 , Edited by admin on Thu Jul 06 22:43:01 UTC 2023
|
||
|
WHO-VATC |
QM02AA18
Created by
admin on Thu Jul 06 22:43:02 UTC 2023 , Edited by admin on Thu Jul 06 22:43:02 UTC 2023
|
||
|
WHO-ATC |
M02AA18
Created by
admin on Thu Jul 06 22:43:01 UTC 2023 , Edited by admin on Thu Jul 06 22:43:01 UTC 2023
|
||
|
CFR |
21 CFR 520.1331
Created by
admin on Thu Jul 06 22:43:01 UTC 2023 , Edited by admin on Thu Jul 06 22:43:01 UTC 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
48I5LU4ZWD
Created by
admin on Thu Jul 06 22:43:01 UTC 2023 , Edited by admin on Thu Jul 06 22:43:01 UTC 2023
|
PRIMARY | |||
|
D008469
Created by
admin on Thu Jul 06 22:43:01 UTC 2023 , Edited by admin on Thu Jul 06 22:43:01 UTC 2023
|
PRIMARY | |||
|
100000081757
Created by
admin on Thu Jul 06 22:43:02 UTC 2023 , Edited by admin on Thu Jul 06 22:43:02 UTC 2023
|
PRIMARY | |||
|
48I5LU4ZWD
Created by
admin on Thu Jul 06 22:43:01 UTC 2023 , Edited by admin on Thu Jul 06 22:43:01 UTC 2023
|
PRIMARY | |||
|
M7120
Created by
admin on Thu Jul 06 22:43:01 UTC 2023 , Edited by admin on Thu Jul 06 22:43:01 UTC 2023
|
PRIMARY | Merck Index | ||
|
2165
Created by
admin on Thu Jul 06 22:43:01 UTC 2023 , Edited by admin on Thu Jul 06 22:43:01 UTC 2023
|
PRIMARY | |||
|
7219
Created by
admin on Thu Jul 06 22:43:01 UTC 2023 , Edited by admin on Thu Jul 06 22:43:01 UTC 2023
|
PRIMARY | |||
|
DB00939
Created by
admin on Thu Jul 06 22:43:01 UTC 2023 , Edited by admin on Thu Jul 06 22:43:01 UTC 2023
|
PRIMARY | |||
|
95309
Created by
admin on Thu Jul 06 22:43:01 UTC 2023 , Edited by admin on Thu Jul 06 22:43:01 UTC 2023
|
PRIMARY | |||
|
588003
Created by
admin on Thu Jul 06 22:43:02 UTC 2023 , Edited by admin on Thu Jul 06 22:43:02 UTC 2023
|
ALTERNATIVE | |||
|
76230
Created by
admin on Thu Jul 06 22:43:01 UTC 2023 , Edited by admin on Thu Jul 06 22:43:01 UTC 2023
|
PRIMARY | |||
|
644-62-2
Created by
admin on Thu Jul 06 22:43:01 UTC 2023 , Edited by admin on Thu Jul 06 22:43:01 UTC 2023
|
PRIMARY | |||
|
4037
Created by
admin on Thu Jul 06 22:43:02 UTC 2023 , Edited by admin on Thu Jul 06 22:43:02 UTC 2023
|
PRIMARY | |||
|
Meclofenamate
Created by
admin on Thu Jul 06 22:43:01 UTC 2023 , Edited by admin on Thu Jul 06 22:43:01 UTC 2023
|
PRIMARY | |||
|
C61826
Created by
admin on Thu Jul 06 22:43:01 UTC 2023 , Edited by admin on Thu Jul 06 22:43:01 UTC 2023
|
PRIMARY | |||
|
SUB08678MIG
Created by
admin on Thu Jul 06 22:43:01 UTC 2023 , Edited by admin on Thu Jul 06 22:43:01 UTC 2023
|
PRIMARY | |||
|
DTXSID0048559
Created by
admin on Thu Jul 06 22:43:01 UTC 2023 , Edited by admin on Thu Jul 06 22:43:01 UTC 2023
|
PRIMARY | |||
|
6678
Created by
admin on Thu Jul 06 22:43:02 UTC 2023 , Edited by admin on Thu Jul 06 22:43:02 UTC 2023
|
PRIMARY | |||
|
211-419-5
Created by
admin on Thu Jul 06 22:43:01 UTC 2023 , Edited by admin on Thu Jul 06 22:43:01 UTC 2023
|
PRIMARY | |||
|
6710
Created by
admin on Thu Jul 06 22:43:01 UTC 2023 , Edited by admin on Thu Jul 06 22:43:01 UTC 2023
|
PRIMARY | |||
|
CHEMBL509
Created by
admin on Thu Jul 06 22:43:01 UTC 2023 , Edited by admin on Thu Jul 06 22:43:01 UTC 2023
|
PRIMARY | |||
|
1650
Created by
admin on Thu Jul 06 22:43:01 UTC 2023 , Edited by admin on Thu Jul 06 22:43:01 UTC 2023
|
PRIMARY |
ACTIVE MOIETY
METABOLITE ACTIVE (PARENT)
METABOLITE INACTIVE (PARENT)
SALT/SOLVATE (PARENT)
